<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>Lymphocyte Signalling and Development</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DBA15943-8B45-46D9-873F-346B6F0996FB"><gtr:id>DBA15943-8B45-46D9-873F-346B6F0996FB</gtr:id><gtr:firstName>Elena</gtr:firstName><gtr:surname>Vigorito</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001781"><gtr:id>01321969-D7C8-45AB-AB0F-8295240898B9</gtr:id><gtr:title>MiRNA-155 regulates B cell function through its target PU.1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001781</gtr:grantReference><gtr:abstractText>MicroRNAs are a recently discovered type of molecule increasingly recognised as being essential for many biological processes. They are important regulators of the immune response. Not surprisingly, deregulation of miRNA function has been linked with malignant transformation and autoimmunity. The knowledge obtained in this project will provide insights into a new mechanism of cell regulation which in the long term may impact in the design of more effective vaccines or for treatment of human diseases.</gtr:abstractText><gtr:technicalSummary>MiRNAs (miRNAs) are increasingly being recognised as major regulators of gene expression. Their expression provides an additional level of regulation beyond transcriptional control, permitting more rapid establishment of stable gene expression patterns. It is now apparent that miRNAs regulate many aspects of the immune system, including adaptive immune responses. During the course of adaptive immune responses B lymphocytes must respond rapidly to antigenic stimulation by initiating complex changes in gene expression that allow differentiation into effector and memory cells. These events lead to the production of high affinity antibodies and development of lasting immunological protection which underpins effective vaccination. The present work aims to test for a functional relation between a particular miRNA, miR-155, and one of its targets, PU.1. My previous work has implicated miR-155 for optimal adaptive immune responses of B cells in a cell-autonomous manner. I have shown that miR-155 is required for optimal immunoglobulin class switch recombination (CSR) and identified the transcription factor PU.1 as miR-155 direct target. In this project, I present some unpublished data establishing a causal relation of miR-155 and its target PU.1 for regulating CSR. I propose to follow up those observations by performing a thorough analysis of the significance of those observations in the context of adaptive immunity in vivo and to understand the molecular mechanisms by which miR-155 through its target PU.1 regulates the generation of switched B cells. The prospect of targeting miRNAs for therapeutic use is exciting and could open up new complementary treatments for cancer, inflammation or effective vaccination. There is already an antagonist for a miRNA in clinical trials for the treatment of hepatitis C. The proposed work will contribute to uncover the regulatory network regulated by miR-155 through its target PU.1 which may be exploited for effective vaccination.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-25</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>624702</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>school teachers visiting babraham institute</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>2BC3724F-EC28-4331-AF29-16853AEAEEBB</gtr:id><gtr:impact>20 teachers attended scientific talks

the scheme will be repeated this year</gtr:impact><gtr:outcomeId>kBhcvapds4j</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Students visit at BI</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F986A8EE-D3E5-4422-B674-0F33A71D8B27</gtr:id><gtr:impact>groups of 10-12 students attended hands-on lab work which inspired pupils to work in science

Schools asked to repeat the experience</gtr:impact><gtr:outcomeId>GAzUdiEpRnE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2A609CD4-66B2-40A1-A611-E62CA56E6ADE</gtr:id><gtr:title>MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb288c1f5870c43259008f17fc02a375"><gtr:id>bb288c1f5870c43259008f17fc02a375</gtr:id><gtr:otherNames>Nakagawa R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>585d66ae8dbba5.93314238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7340E677-E298-4770-8546-96633A9CD119</gtr:id><gtr:title>The miR-155-PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b547807318acd5f0dc3ba27c7fe7636a"><gtr:id>b547807318acd5f0dc3ba27c7fe7636a</gtr:id><gtr:otherNames>Lu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>546390bb012c18.25052617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C8E81A8-96A8-4A42-A496-219256562141</gtr:id><gtr:title>MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b547807318acd5f0dc3ba27c7fe7636a"><gtr:id>b547807318acd5f0dc3ba27c7fe7636a</gtr:id><gtr:otherNames>Lu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14154_24_22912667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03D221A-A749-4E72-BA13-84BD19C83E93</gtr:id><gtr:title>Noncoding RNA and its associated proteins as regulatory elements of the immune system.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6908988a9a607232738eabea8393d78"><gtr:id>d6908988a9a607232738eabea8393d78</gtr:id><gtr:otherNames>Turner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>54185abd945680.97217772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFF74DD8-1FD9-4E8D-91E0-525087D47782</gtr:id><gtr:title>miRNA-155 controls mast cell activation by regulating the PI3K? pathway and anaphylaxis in a mouse model.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0aaf6ec12208981c4eaf7e4c71b127f"><gtr:id>c0aaf6ec12208981c4eaf7e4c71b127f</gtr:id><gtr:otherNames>Biethahn K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>54185abdcb95a3.28877841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA8E70B-24F5-4B94-B1C0-356645FD7FAD</gtr:id><gtr:title>miR-155: an ancient regulator of the immune system.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba11c6db7f4c1011f6d86abb62b41938"><gtr:id>ba11c6db7f4c1011f6d86abb62b41938</gtr:id><gtr:otherNames>Vigorito E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_14154_24_23550644</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001781</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>